RankingsPricing
  1. US-listed companies
  2. Akebia Therapeutics, Inc.
  3. Financials
  4. Stock-based compensation

Akebia Therapeutics, Inc.AKBA

Market cap
$438.6M
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 20248-16.55%
Dec 31, 20239-47.80%
Dec 31, 202218-21.49%
Dec 31, 202123-7.05%
Dec 31, 202024+105.12%
Dec 31, 201912-37.37%
Dec 31, 201819+114.73%
Dec 31, 20179+52.22%
Dec 31, 20166+23.57%
Dec 31, 20155-21.56%
Dec 31, 20146

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)